Peyronie’s disease: pharmacological treatments and limitations
The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Introduction: Peyronie’s disease (PD) is a disorder of the tunica albuginea from disordered and excessive deposition of collagen resulting in a palpable scar, pain, erect penile deformity and erectile dysfunction that significantly impacts patients both physically and emotionally.Areas Covered: Several treatment options have been described for PD, including shockwave therapy, traction therapy, both oral and intralesional pharmacological options, and surgery. This review seeks to examine the data for different types of non-surgical treatments for PD. We review how various treatment modalities impact several relevant clinical endpoints for Peyronie’s disease, including effects on pain, penile curvature, plaque formation, and erectile function. We performed a literature search using PubMed and SCOPUS while referencing AUA, EAU, and CUA guidelines for management of Peyronie’s Disease for studies published 1980–2020.Expert opinion: Intralesional collagenase injections have the strongest evidence and are the only FDA approved intralesional treatment for PD. Penile traction therapy (PTT) is low risk and may be beneficial in patients willing to invest significant time using the devices. Furthermore, oral combination therapy with other modalities may provide some benefit. Further investigation is required to better understand pathophysiology of PD and clarify the therapeutic utility of existing treatments, potentially with a multimodal strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Penile traction therapy is a nonsurgical treatment option for PD that involves applying consistent traction forces to gradually straighten penile curvature and improve symptoms.133”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [133]
In the citing paper
“Pentoxifylline, an antifibrotic agent, modulates fibrosis by suppressing inflammation, inhibiting TGF-β activation, and reducing collagen synthesis.133”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [133]
In the citing paper
“Common treatment methods for penile induration include medication therapy, injection therapy, and surgical treatment.133,147,148”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [133]
Citations
Cites
Transforming growth factor-beta in disease: the dark side of tissue repair.
Border, W. A., & Ruoslahti, E. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115821 · Cited by 1,105
Pathways of Protein Secretion in Eukaryotes
Kelly, R. B. (1985) · Science · doi:10.1126/science.2994224 · Cited by 1,052
Extracorporeal shockwave therapy in musculoskeletal disorders
Wang, C.-J. (2012) · Journal of Orthopaedic Surgery and Research · doi:10.1186/1749-799x-7-11 · Cited by 527
Gelbard, M., Goldstein, I., Hellstrom, W. J. G., McMahon, C. G., Smith, T., Tursi, J., Jones, N., Kaufman, G. J., & Carson, C. C. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.01.087 · Cited by 466
Peyronie’s Disease: AUA Guideline
Nehra, A., Alterowitz, R., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J. J., Khera, M., Kirkby, E., McVary, K. T., Miner, M. M., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.05.098 · Cited by 416
Colletta, A., Wakefield, L., Howell, F., van Roozendaal, K., Danielpour, D., Ebbs, Sr., Sporn, M., & Baum, M. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.307 · Cited by 318
EAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309 · cited 2×
“direct force on the plaque, leading to mechanical induced remodeling and plaque lysis, and also promotes angiogenesis, leading to increased availability of inflammatory mediators causing plaque lysis and absorption [30,33].”
BackgroundThe Incidence of Peyronie’s Disease in Rochester, Minnesota, 1950 through 1984
Lindsay, M. B., Schain, D. M., Grambsch, P., Benson, R. C., Beard, C. M., & Kurland, L. T. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)37988-0 · Cited by 265
McCarty, M. F. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0684 · Cited by 234
Hellstrom, W. J. G., Kendirci, M., Matern, R., Cockerham, Y., Myers, L., Sikka, S. C., Venable, D., Honig, S., McCullough, A., Hakim, L. S., et al. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00517-9 · Cited by 223
Valente, E. G. A., Vernet, D., Ferrini, M. G., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2003) · Nitric Oxide · doi:10.1016/j.niox.2003.12.002 · Cited by 223
Intralesional Verapamil Injection for the Treatment of Peyronie’s Disease
Levine, L. A., Merrick, P. F., & Lee, R. C. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35291-6 · Cited by 207
Self-citationTAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE
TELOKEN, C., RHODEN, E. L., GRAZZIOTIN, T. M., DA ROS, C. T., SOGARI, P. R., & SOUTO, C. A. V. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68087-1 · Cited by 201
Use of Intralesional Verapamil to Dissolve Peyronie’s Disease Plaque: A Long-Term Single-Blind Study
Rehman, J., Benet, A., & Melman, A. (1998) · Urology · doi:10.1016/s0090-4295(97)00700-0 · Cited by 201
Weidner, W., Hauck, E. W., & Schnitker, J. (2005) · European Urology · doi:10.1016/j.eururo.2004.12.022 · Cited by 196
Palmieri, A., Imbimbo, C., Longo, N., Fusco, F., Verze, P., Mangiapia, F., Creta, M., & Mirone, V. (2009) · European Urology · doi:10.1016/j.eururo.2009.05.012 · Cited by 189
Experience With Intraplaque Injection of Verapamil for Peyronie’s Disease
Levine, L. A., Goldman, K. E., & Greenfield, J. M. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64691-5 · Cited by 185
Self-citationAntioxidant effect of l-carnitine and its short chain esters
Calò, L. A., Pagnin, E., Davis, P. A., Semplicini, A., Nicolai, R., Calvani, M., & Pessina, A. C. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.053 · Cited by 161
Fibrin Deposition in Peyronie's Disease Plaque
Somers, K. D., & Dawson, D. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65367-9 · Cited by 160
Is colchicine effective in Peyronie'sdisease? A pilot study
Akkuş, E., Breza, J., Jr., Carrier, S., Kadıoğlu, A., Rehman, J., & Lue, T. F. (1994) · Urology · doi:10.1016/s0090-4295(94)80155-x · Cited by 154
The Treatment of Peyronie's Disease with Tamoxifen
RALPH, D. J., BROOKS, M. D., BOTTAZZO, G. F., & PRYOR, J. P. (1992) · British Journal of Urology · doi:10.1111/j.1464-410x.1992.tb15836.x · Cited by 154
Penile Traction Therapy for Treatment of Peyronie's Disease: A Single-Center Pilot Study
Levine, L. A., Newell, M., & Taylor, F. L. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00814.x · Cited by 150
Self-citationFibrin Deposition in Peyronie's Disease Plaque
Somers, K. D., & Dawson, D. M. (1997) · The Journal of Urology · doi:10.1097/00005392-199701000-00104 · Cited by 144
Acetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report
Biagiotti, G., & Cavallini, G. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02241.x · Cited by 142
The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction
Arafa, M. M., Eid, H., El-Badry, A., Ezz-Eldine, K., & Shamloul, R. M. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901518 · Cited by 137
Calcium antagonists retard extracellular matrix production in connective tissue equivalent
Lee, R. C., & Jiang, P. (1990) · Journal of Surgical Research · doi:10.1016/0022-4804(90)90197-a · Cited by 134
Duncan, M. R., Berman, B., & Nseyo, U. O. (1991) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365599109024539 · Cited by 132
Martínez-Salamanca, J. I., Egui, A., Moncada, I., Minaya, J., Ballesteros, C. M., del Portillo, L., Sola, I., & Carballido, J. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12400 · Cited by 129
Shirazi, M., Haghpanah, A., Badiee, M., Afrasiabi, M. A., & Haghpanah, S. (2009) · International Urology and Nephrology · doi:10.1007/s11255-009-9522-4 · Cited by 128
Treatment of Renal Stones by Extracorporeal Shockwave Lithotripsy
Rassweiler, J. J., Renner, C., Chaussy, C., & roff, S. T. U. (2001) · European Urology · doi:10.1159/000052435 · Cited by 128
Safarinejad, M. R., Hosseini, S. Y., & Kolahi, A. A. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.05.162 · Cited by 127
Greenfield, J. M., Shah, S. J., & Levine, L. A. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.10.065 · Cited by 124
Self-citationCombination of Penile Traction, Intralesional Verapamil, and Oral Therapies for Peyronie’s Disease
Abern, M. R., Larsen, S., & Levine, L. A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02519.x · Cited by 121
Self-citationSafarinejad, M. R. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901185 · Cited by 120
Lipshultz, L. I., Goldstein, I., Seftel, A. D., Kaufman, G. J., Smith, T. M., Tursi, J. P., & Burnett, A. L. (2015) · BJU International · doi:10.1111/bju.13096 · Cited by 120
Collagenase for Peyronie's disease experimental studies
Gelbard, M. K., Walsh, R., & Kaufman, J. (1982) · Urological Research · doi:10.1007/bf00255956 · Cited by 119
The Use of Collagenase in the Treatment of Peyronie’s Disease
Gelbard, M. K., Lindner, A., & Kaufman, J. J. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)47123-0 · Cited by 118
Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease
Prieto Castro, R. M., Leva Vallejo, M. E., Regueiro Lopez, J. C., Anglada Curado, F. J., Alvarez Kindelan, J., & Requena Tapia, M. J. (2003) · BJU International · doi:10.1046/j.1464-410x.2003.04134.x · Cited by 117
Hatzichristodoulou, G., Meisner, C., Gschwend, J. E., Stenzl, A., & Lahme, S. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12275 · Cited by 113
TREATMENT OF PEYRONIE'S DISEASE WITH INTRALESIONAL VERAPAMIL INJECTION
Levine, L. A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64224-1 · Cited by 112
Self-citationDI STASI, S. M., GIANNANTONI, A., STEPHEN, R. L., CAPELLI, G., GIURIOLI, A., JANNINI, E. A., & VESPASIANI, G. (2004) · Journal of Urology · doi:10.1097/01.ju.0000116450.82816.2c · Cited by 111
Kadıoğlu, A., TEFEKLİ, A. H., Köksal, T., Usta, M. F., & Erol, H. (2000) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900519 · Cited by 110
Palmieri, A., Imbimbo, C., Creta, M., Verze, P., Fusco, F., & Mirone, V. (2012) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01226.x · Cited by 109
Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy
Liu, T., Shindel, A. W., Lin, G., & Lue, T. F. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0113-3 · Cited by 106
MARTIN, D. J., BADWAN, K., PARKER, M., & MULHALL, J. P. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64173-0 · Cited by 99
Chung, E., DeYoung, L., & Brock, G. B. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02217.x · Cited by 98
The Natural History of Peyronie's Disease: An Ultrasonography-Based Study
Bekos, A., Arvaniti, M., Hatzimouratidis, K., Moysidis, K., Tzortzis, V., & Hatzichristou, D. G. (2007) · European Urology · doi:10.1016/j.eururo.2007.07.013 · Cited by 96
Chitale, S., Morsey, M., Swift, L., & Sethia, K. (2010) · BJU International · doi:10.1111/j.1464-410x.2010.09331.x · Cited by 94
Intralesional Verapamil Prevents the Progression of Peyronie’s Disease
Bennett, N., Guhring, P., & Mulhall, J. P. (2007) · Urology · doi:10.1016/j.urology.2007.02.042 · Cited by 91
Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy
González-Cadavid, N. F., & Rajfer, J. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.24 · Cited by 90
Transdermal Electromotive Multi‐Drug Administration for Peyronie's Disease: Preliminary Results
MONTORSI, F., SALONIA, A., GUAZZONI, G., BARBIERI, L., COLOMBO, R., BRAUSI, M., SCATTONI, V., RIGATTI, P., & PIZZINI, G. (2000) · Journal of Andrology · doi:10.1002/j.1939-4640.2000.tb03279.x · Cited by 87
Pathophysiology of Peyronie's disease
Moreland, R. B., & Nehra, A. X. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900875 · Cited by 86
Fitch, Easterling, W. J., Talbert, R. L., Bordovsky, M. J., & Mosier, M. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00417.x · Cited by 84
Pentoxifylline treatment and penile calcifications in men with Peyronie's disease
Smith, J. F., Shindel, A. W., Huang, Y.-C., Clavijo, R. I., Flechner, L., Breyer, B. N., Eisenberg, M. L., & Lue, T. F. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2010.117 · Cited by 76
A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease
Gao, L., Qian, S., Tang, Z., Li, J., & Yuan, J. (2016) · International Journal of Impotence Research · doi:10.1038/ijir.2016.24 · Cited by 72
Treatment of Peyronie's Disease with Local lnterferon-a2b
Wegner, H., Andresen, R., Knipsel, H. H., & Miller, K. (1995) · European Urology · doi:10.1159/000475057 · Cited by 72
Ziegelmann, M., Savage, J., Toussi, A., Alom, M., Yang, D., Kohler, T., & Trost, L. (2019) · Journal of Urology · doi:10.1097/ju.0000000000000245 · Cited by 72
Del Carlo, M., Cole, A. A., & Levine, L. A. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.01.093 · Cited by 69
Self-citationNguyen, H. M. T., Anaissie, J., DeLay, K. J., Yafi, F. A., Sikka, S. C., & Hellstrom, W. J. G. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.08.008 · Cited by 69
Moncada, I., Krishnappa, P., Romero, J., Torremade, J., Fraile, A., Martinez‐Salamanca, J. I., Porst, H., & Levine, L. (2019) · BJU International · doi:10.1111/bju.14602 · Cited by 69
Self-citationKendirci, M., Usta, M. F., Matern, R. V., Nowfar, S., Sikka, S. C., & Hellstrom, W. J. G. (2005) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2005.00110.x · Cited by 68
Paulis, G., Brancato, T., D'Ascenzo, R., De Giorgio, G., Nupieri, P., Orsolini, G., & Alvaro, R. (2013) · Andrology · doi:10.1111/j.2047-2927.2012.00007.x · Cited by 67
RIEDL, C. R., Sternig, P., Gallè, G., Langmann, F., Vcelar, B. A., Vorauer, K., Wagner, A., Katinger, H. W. D., & Pflüger, H. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.011 · Cited by 66
Painful ulcers in calciphylaxis – combined treatment with maggot therapy and oral pentoxyfillin
J Tittelbach, T. G., Graefe, T., & Wollina, U. (2001) · Journal of Dermatological Treatment · doi:10.1080/09546630152696035 · Cited by 65
Stewart, C. A., Yafi, F. A., Knoedler, M., Mandava, S. H., McCaslin, I. R., Sangkum, P., Sikka, S., Trost, L., & Hellstrom, W. J. G. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.06.096 · Cited by 64
The Immunological Features of Peyronie's Disease
Ralph, D. J., Mirakian, R., Pryor, J. P., & Bottazzo, G. F. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)66582-0 · Cited by 63
Gokce, A., Abd Elmageed, Z. Y., Lasker, G. F., Bouljihad, M., Braun, S. E., Kim, H., Kadowitz, P. J., Abdel-Mageed, A. B., Sikka, S. C., & Hellstrom, W. J. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12916 · Cited by 62
Abdelsalam, Y. M., Budair, Z., RENNER, C., Frede, T., Rassweiler, J. J., EL-ANNANY, F., EL-MAGRABY, H., & El-Akkad, M. (1999) · Journal of Endourology · doi:10.1089/end.1999.13.549 · Cited by 59
Tunica Albuginea Tissue Analysis After Electromotive Drug Administration
LEVINE, L. A., ESTRADA, C. R., SHOU, W., & COLE, A. (2003) · Journal of Urology · doi:10.1097/01.ju.0000056153.47716.d0 · Cited by 59
Self-citationTHE EFFECTS OF COLCHICINE ON A PEYRONIE'S-LIKE CONDITION IN AN ANIMAL MODEL
EL-SAKKA, A. I., BAKIRCIOGLU, M. E., BHATNAGAR, R. S., YEN, T. S. B., DAHIYA, R., & LUE, T. F. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68868-4 · Cited by 57
Twidwell, J., & Levine, L. (2016) · International Journal of Impotence Research · doi:10.1038/ijir.2015.22 · Cited by 51
Self-citationOutcomes of Intralesional Interferon-α2B for the Treatment of Peyronie Disease
Trost, L. W., Ates, E., Powers, M., Sikka, S., & Hellstrom, W. J. G. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.022 · Cited by 50
WNT2 Locus is Involved in Genetic Susceptibility of Peyronie’s Disease
Dolmans, G. H., Werker, P. M., de Jong, I. J., Nijman, R. J., Study, L. C., Wijmenga, C., & Ophoff, R. A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02704.x · Cited by 46
Favilla, V., Russo, G. I., Privitera, S., Castelli, T., Madonia, M., La Vignera, S., Condorelli, R., Calogero, A. E., Farina, F. P., Cimino, S., et al. (2014) · Andrologia · doi:10.1111/and.12178 · Cited by 45
Mehrsai, A. R., Namdari, F., Salavati, A., Dehghani, S., Allameh, F., & Pourmand, G. (2013) · Andrology · doi:10.1111/j.2047-2927.2012.00018.x · Cited by 44
A brief historical survey of “Peyronie’s disease.”
Musitelli, S., Bossi, M., & Jallous, H. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00692.x · Cited by 43 · cited 2×
“However, there are descriptions of the disease many centuries prior, as far back as the 13 century by Theodoricus Borgognoni and Guilielmus Saliceto [3].”
BackgroundEffect of Penile Traction and Vacuum Erectile Device for Peyronie’s Disease in an Animal Model
Lin, H., Liu, C., & Wang, R. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.08.011 · Cited by 41
Hellstrom, W. J. G., Tue Nguyen, H. M., Alzweri, L., Chung, A., Virasoro, R., Tapscott, A., Ziegelmann, M., Trost, L., & Gelbard, M. (2019) · Journal of Urology · doi:10.1097/ju.0000000000000032 · Cited by 38
IMMUNOMODULATORY EFFECT OF PENTOXIFYLLINE DURING HUMAN ALLOGRAFT REJECTION
Noël, C., Copin, M., Hazzan, M., Labalette, M., Susen, S., Lelievre, G., & Dessaint, J. (2000) · Transplantation · doi:10.1097/00007890-200003270-00014 · Cited by 31
Ziegelmann, M. J., Trost, L. W., Russo, G. I., & Levine, L. A. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.11.271 · Cited by 31 · cited 1×
“a consensus as to what is considered a ‘clinically meaningful’ change in the PD literature [93].”
BackgroundSelf-citationOutcome analysis for conservative management of Peyronie's disease
Hashimoto, K., Hisasue, S., Kato, R., Kobayashi, K., Shimizu, T., & Tsukamoto, T. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01270.x · Cited by 30
Nguyen, H. M. T., Hellstrom, W. J. G., Alzweri, L. M., Chung, A. S. J., Virasoro, R., Tapscott, A. H., Ziegelmann, M., Trost, L. W., & Gelbard, M. K. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.01.118 · Cited by 25
Penile Stretching as a Treatment for Peyronie’s Disease: A Review
Cowper, M. G., Burkett, C. B., Le, T. V., Scherzer, N., & Hellstrom, W. J. G. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.11.002 · Cited by 23
(2015) · BJU International · doi:10.1111/bju.13063 · Cited by 16
Androutsos, G. (2002) · PubMed · Cited by 16
Gallo, L., & Sarnacchiaro, P. (2019) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2018.08.005 · Cited by 16
RIEDL, C. R., Plas, E., Vorauer, K., Vcelar, B. A., Wagner, A., & GER, H. P. (2001) · European Urology · doi:10.1159/000049797 · Cited by 12
Advances in stem cell therapy for the treatment of Peyronie's disease
Moussa, M., Chakra, M. A., & Moussa, Y. (2020) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2019.01130 · Cited by 10
Levine, L. A. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00539.x · Cited by 9
Self-citation
Research works printed but not linked: 7
- Androutsos G., 2002, Prog Urol, 12, 527
- Dibenedetti DB, 2011, Adv Urol, 282503, 2011
- Bellorofonte C, 1989, Arch Ital Urol Nefrol Androl, 61, 417
- Bella AJ, 2018, Can Urol Assoc J, 12, 2018
- Scroppo FI, 2001, Int J Impot Res, 13
- Pavan A, 2020, StatPearls [Internet]
- Vacante F, 2018, J UDiabetes Res, 4028297, 2018
Cited by
Collagen-based materials in male genitourinary diseases and tissue regeneration
Li, F., XinHuang, Wang, R., Li, Y., Wu, L., Qiao, X., Zhong, Y., Gong, G., & Huang, W. (2024) · Collagen and Leather · doi:10.1186/s42825-024-00185-3 · Cited by 18
Rossi, A., Leone, A. G., Lambertini, M., Sperti, E., Cassani, C., Vetromile, A., Barni, S., Giorgi, A. D., Preti, E. P., Secondino, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105311 · Cited by 17
Chi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae006 · Cited by 14
Ilg, M. M., Lapthorn, A. R., Ralph, D. J., & Cellek, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277646 · Cited by 12
KARAKOSE, A., & YİTGİN, Y. (2024) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.23.05458-7 · Cited by 11
Metadata
- Authors
- Li, E. V., Esterquest, R., Pham, M. N., Panken, E. J., Amarasekera, C., Siebert, A., Bajic, P., & Levine, L. A.
- Affiliations
- Northwestern University (US)
- Rush University Medical Center (US)
- Cleveland Clinic (US)
- Corresponding author
- Amarasekera, Channa
- ORCID
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-03-25
- Volume
- 14
- Issue
- 6
- Pages
- 703-713
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3136796051
- Cited by
- 24
- References
- 89
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 11 · 2023: 7 · 2022: 2
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Keywords
- Peyronie's disease, penile traction therapy, shock wave therapy, oral combination therapy, penile curvature, erectile dysfunction, penile pain, tunica albuginea, collagen deposition, conservative treatment
- MeSH terms
- Extracorporeal Shockwave Therapy, Animals, Combined Modality Therapy, Humans, Male, Penile Induration, Traction, Injections, Intralesional, Collagenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.